Cargando…

Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer

BACKGROUND: Protective effects have been suggested for digoxin against prostate cancer risk. However, few studies have evaluated the possible effects on prostate cancer-specific survival. We studied the association between use of digoxin or beta-blocker sotalol and prostate cancer-specific survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaapu, Kalle J, Murtola, Teemu J, Talala, Kirsi, Taari, Kimmo, Tammela, Teuvo LJ, Auvinen, Anssi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129833/ https://www.ncbi.nlm.nih.gov/pubmed/27755533 http://dx.doi.org/10.1038/bjc.2016.328

Ejemplares similares

Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer
por: Kinnunen, Pete T. T., et al.
Publicado: (2017)

Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial
por: Veitonmäki, Thea, et al.
Publicado: (2016)

Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer
por: Murtola, Teemu J., et al.
Publicado: (2018)

Antihypertensive drug use and prostate cancer-specific mortality in Finnish men
por: Siltari, Aino, et al.
Publicado: (2020)

Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men
por: Kaapu, Kalle J., et al.
Publicado: (2018)

Prostate cancer incidence in men with prostate‐specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer
por: Ola, Idris Olasunmbo, et al.
Publicado: (2022)

Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer
por: Salminen, Jukka K., et al.
Publicado: (2022)

Long‐term health‐related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer
por: Talala, Kirsi, et al.
Publicado: (2020)

Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level
por: Peltomaa, Antti I., et al.
Publicado: (2022)

Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time
por: Pylväläinen, Juho, et al.
Publicado: (2019)

Prostate cancer risk prediction using a polygenic risk score
por: Sipeky, Csilla, et al.
Publicado: (2020)

Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation
por: Neupane, Subas, et al.
Publicado: (2021)

Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial
por: Veitonmäki, T, et al.
Publicado: (2014)

Outcomes of prostate cancer screening among men using antidiabetic medication
por: Vettenranta, A., et al.
Publicado: (2021)

Statin use and outcomes of oncological treatment for castration-resistant prostate cancer
por: Peltomaa, A. I., et al.
Publicado: (2023)

Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data
por: Booth, Neill, et al.
Publicado: (2019)

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study
por: Peltomaa, A. I., et al.
Publicado: (2021)

Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial
por: Murtola, T J, et al.
Publicado: (2009)

Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC
por: Pashayan, Nora, et al.
Publicado: (2015)

False-positive screening results in the Finnish prostate cancer screening trial
por: Kilpeläinen, T P, et al.
Publicado: (2010)

Pharmacoepidemiological Evaluation in Prostate Cancer—Common Pitfalls and How to Avoid Them
por: Siltari, Aino, et al.
Publicado: (2021)

Population‐based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study
por: Rannikko, Antti, et al.
Publicado: (2022)

Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease
por: Sipeky, Csilla, et al.
Publicado: (2021)

PALB2 variants in hereditary and unselected Finnish Prostate cancer cases
por: Pakkanen, Sanna, et al.
Publicado: (2009)

Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study
por: Hietikko, Ronja, et al.
Publicado: (2020)

Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial
por: Raittinen, Paavo V.H., et al.
Publicado: (2021)

Missingness in the expanded prostate cancer index short form (EPIC-26) – prevalence, patterns, and explanatory factors
por: Talvitie, Anna-Maija, et al.
Publicado: (2023)

Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial
por: Määttänen, L, et al.
Publicado: (2007)

MiRNA Profiles in Lymphoblastoid Cell Lines of Finnish Prostate Cancer Families
por: Fischer, Daniel, et al.
Publicado: (2015)

Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation
por: Nätkin, Reetta, et al.
Publicado: (2023)

European randomized study of prostate cancer screening: first-year results of the Finnish trial
por: Määttänen, L, et al.
Publicado: (1999)

The Importance of LDL and Cholesterol Metabolism for Prostate Epithelial Cell Growth
por: Murtola, Teemu J., et al.
Publicado: (2012)

Overall and worst gleason scores are equally good predictors of prostate cancer progression
por: Tolonen, Teemu T, et al.
Publicado: (2011)

Impact of cause of death adjudication on the results of the European prostate cancer screening trial
por: Walter, Stephen D, et al.
Publicado: (2017)

Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases
por: Sattari, Mina, et al.
Publicado: (2023)

Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer
por: Godtman, Rebecka Arnsrud, et al.
Publicado: (2021)

Prostate cancer screening: what can we learn from randomised trials?
por: Auvinen, Anssi
Publicado: (2018)

Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system
por: Eskelinen, Tommi, et al.
Publicado: (2021)

Assessing Interactions of Two Loci (rs4242382 and rs10486567) in Familial Prostate Cancer: Statistical Evaluation of Epistasis
por: Chen, Li-Sheng, et al.
Publicado: (2014)

Is the Prevalence of Overactive Bladder Overestimated? A Population-Based Study in Finland
por: Tikkinen, Kari A.O., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_rhni93m1jaj5ib2qn842bghvdv